Safety Study of GPX-150 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD)
and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once
every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose
of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment.
Patients who have previously received an anthracycline are limited to 4 cycles of treatment.